Single peptide Vial strength 2 mg
CJC-1295 DAC2 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
CJC-1295 DAC, explained simply
A longer-acting GHRH analogue. Its DAC modification distinguishes it from the shorter-acting version.
Research area
GH/IGF-1 axis
How it works
Binds pituitary GHRH receptors; the DAC modification supports albumin binding and a longer time in circulation.
Why it matters
It is studied for the duration of GH and IGF-1 responses and related metabolic processes.
What has been observed
Human studies show increases in GH and IGF-1 following CJC-1295 DAC administration.
Effects and points to consider
A measured hormonal response does not automatically translate into clinical benefits for body composition or recovery.
01 / Vial strength 2 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 2 mg CJC-1295 DAC |
|---|---|
| Final volume | 1 mL |
| Concentration | 2 mg/mL |
| One U-100 unit | 20 mcg in 0.01 mL |
Standard Weekly Approach (1 mL = 2.0 mg/mL)
| Week | Weekly Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–12 | 2,000 mcg (2 mg) | 100 units (1.00 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.